Cowen & Co. analyst Yaron Werber maintained a Buy rating on Amgen Inc (AMGN) yesterday and set a price target of $231.00. The company’s shares closed last Monday at $204.83, close to its 52-week high of $211.90.
According to TipRanks.com, Werber is a 4-star analyst with an average return of 6.7% and a 55.3% success rate. Werber covers the Healthcare sector, focusing on stocks such as Ultragenyx Pharmaceutical, Inc., Springworks Therapeutics Inc, and Rocket Pharmaceuticals Inc.
Currently, the analyst consensus on Amgen Inc is a Moderate Buy with an average price target of $220.85, implying a 7.9% upside from current levels. In a report issued on October 14, Bernstein also resumed coverage with a Buy rating on the stock.
See today’s analyst top recommended stocks >>
Amgen Inc’s market cap is currently $122.8B and has a P/E ratio of 16.22. The company has a Price to Book ratio of 11.43.
Based on the recent corporate insider activity of 83 insiders, corporate insider sentiment is negative on the stock. This means that over the past quarter there has been an increase of insiders selling their shares of AMGN in relation to earlier this year.
TipRanks has tracked 36,000 company insiders and found that a few of them are better than others when it comes to timing their transactions. See which 3 stocks are most likely to make moves following their insider activities.
